Fig. 5

a The percentages of CD4⁺ were determined in the splenocytes. b The percentages of CD8⁺ were determined in the splenocytes. c The percentages of CD4⁺CD25⁺Foxp3⁺ Tregs were determined in the splenocytes of the WT PBS-treated wild type group, 3xTg 3xTg group, donepezil donepezil-treated 3xTg group, bvPLA2 0.2 bvPLA2 0.2 mg/kg-treated 3xTg group, 3xTg+bvPLA2 bvPLA2 1 mg/kg-treated 3xTg group. To deplete the Tregs, PC61 anti-CD25 mAb (1 mg/kg) was i.p. injected for 3 months once a week until they were 6 months old. The error bars represent the SEMs. ***P < 0.001 compared to the WT groups; ^## P < 0.01, ^### P < 0.001 compared to the 3xTg group (one-way ANOVA with Tukey’s post hoc analyses). d Retention performance was tested on fourth day. In the retention test, the mice received a probe trial in which the platform was removed from the pool. e The brain sections were prepared and immunostained with Aβ antibody to identify the Aβ deposits in CA1. f The Aβ in the hippocampal CA3 region as detected with immunohistochemical staining with using anti-Aβ antibody. g Measured depositions of Aβ in CA1. h Measured depositions of Aβ in CA3. The error bars represent the SEMs. *P < 0.05 and **P < 0.01 (two-way ANOVA with Tukey’s posttests). IgG1 normal rat IgG1, PC61 PC61 anti-CD25 monoclonal antibody